{"id":"W2763012859","doi":"10.1200/jco.2017.35.15_suppl.9093","title":"Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Oncology; Rash; Adverse effect; Diarrhea; Cohort; Ipilimumab; Gastroenterology; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162976,0.0005457927,0.0008135949,0.0002391176,0.0002946387,0.0007405787,0.0006083695,0.0006765356,0.001636502],"category_scores_gemma":[0.000584172,0.0002330503,0.0009355503,0.0002371195,0.000437898,0.000593315,0.000346949,0.001672534,0.0003874745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026287,"about_ca_system_score_gemma":0.0007499905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001694329,"about_ca_topic_score_gemma":0.004106164,"domain_scores_codex":[0.999769,0.00009538296,0.00001337914,0.00004297,0.00003114247,0.00004812766],"domain_scores_gemma":[0.999514,0.0000725529,0.0001120988,0.00003515288,0.00001968922,0.000246576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5669652,0.05716122,0.064693,0.0009305359,0.0021142,0.0007299919,0.0005536938,0.005272951,0.05251556,0.0002199491,0.007463342,0.2413803],"study_design_scores_gemma":[0.1429548,0.6697381,0.1686302,0.0001041205,0.001348175,0.0009717582,0.0001297727,0.003524702,0.007083938,0.0001591467,0.005288603,0.00006675864],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974935,0.001079375,0.00008276492,0.000114033,0.00002453164,0.0001402726,0.0004512957,0.00001531691,0.0005989728],"genre_scores_gemma":[0.9964759,0.0006327929,0.0002265179,0.0002733724,0.00005099241,0.0001347749,0.001416197,0.000006843822,0.0007825598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001694329,"threshold_uncertainty_score":0.007446289,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1794170595580584,"score_gpt":0.4993057137901145,"score_spread":0.3198886542320561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}